Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer.
Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer.
复制标题
DOI：
10.1158/1055-9965.epi-15-0547
复制
发表时间：
2015-09
期刊：
影响因子：
--
通讯作者：
Li CI
中科院分区：
文献类型：
--
作者：
Chen L;Malone KE;Li CI
降压药在美国成年人中广泛使用，有一些证据表明，某些类别的药物可能会影响乳腺癌预后不良的风险，但它们对第二原发对侧乳腺癌风险的影响尚不清楚。我们使用了一项基于人群的嵌套病例对照研究的数据，该研究包括359名同时被诊断患有第一原发乳腺癌和第二原发对侧乳腺癌的妇女和691名仅被诊断为单一乳腺癌并分别与病例匹配的对照妇女。多变量条件Logistic回归用于估计与各种抗高血压药物的曾经、近期和持续时间相关的风险的优势比和95%可信区间。没有一类抗高血压药物，包括钙通道阻滞剂、β阻滞剂、血管紧张素转换酶抑制剂和利尿剂，与第二原发对侧乳腺癌的风险有关。在一项仅限于有高血压病史的女性的敏感性分析中，这些结果没有实质性的变化。我们的研究结果不支持在雌激素受体阳性的乳腺癌患者中使用各种降压药与CBC风险之间的关联。目前的研究增加了证据，支持乳腺癌幸存者中常用的抗高血压药物在第二原发对侧乳腺癌风险方面的安全性。
Antihypertensive medications are widely used among adults in the U.S. and there is some evidence that certain classes may affect the risk of adverse breast cancer outcomes, but their impact on risk of second primary contralateral breast cancer is unclear. We used data from a population-based nested case-control study consisting of 359 women diagnosed with both a first primary breast cancer and a second primary contralateral breast cancer and 691 control women diagnosed with only a single breast cancer and individually matched to cases. Multivariate conditional logistic regression was used to estimate odds ratios and 95% confidence intervals for risks associated with ever, recency and duration of use for various antihypertensive medications. No class of antihypertensive, including calcium channel blockers, β blockers, ACE inhibitors and diuretics, was associated with risk of second primary contralateral breast cancer. These results did not change materially in a sensitivity analysis restricted to women with a history of hypertension. Our findings do not support associations between use of various antihypertensives and CBC risk among women with estrogen receptor + breast cancer. The present study adds evidence to support the safety of commonly used antihypertensive medications among breast cancer survivors with respect to risk of second primary contralateral breast cancer.